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hospitalized with newly diagnosed autoimmune type 1 dia-
betes. The diagnosis was confirmed by positive assay for at 
least one islet autoantibody: to glutamic acid decarboxylase 
65 (anti-GAD) or to insulinoma-associated antigen (IA2-
Ab) or islet cell antibodies (ICA). Among these, 23 patients 
(19 %) presented with diabetic ketoacidosis (DKA), 
defined according to the ADA 2009 criteria. Informed con-
sent was obtained from all individual participants included 
in the study. Clinical and biochemical characteristics of the 
study group are shown in Table 1.
At diagnosis of diabetes, anthropometric measurements 
were taken and data on the duration of clinical symptoms, 
body weight before onset of symptoms and smoking status 
were collected using a questionnaire. Serum adiponectin 
was measured using ELISA kit (Quantikine, R&D). HbA1c 
was measured using high-performance liquid chromatogra-
phy (normal reference range 4.1–6.4 %). Serum C-peptide 
concentration was determined using immunoenzymatical 
method (IMMULITE, DPC), normal range: 1.1–5.0 ng/ml. 
In statistical analysis (Statistica 10, StatSoft Inc., Tulsa, 
USA) Student’s t test or Mann–Whitney U test, as appro-
priate, were used to compare serum adiponectin concentra-
tion between subgroups. Pearson or Spearman correlation 
coefficients between continuous variables and serum adi-
ponectin concentration was calculated. In the multivari-
ate linear regression model we determined the association 
between serum adiponectin concentration and HbA1c, with 
adjustment for sex and variables that reflect catabolism and 
inflammation.
Results
Serum adiponectin concentration at diagnosis was 
higher in women than in men (mean ± SD: 8.07 ± 4.31 
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Background and aims
Serum adiponectin concentration is higher in patients with 
type 1 diabetes (T1DM) when compared with healthy, 
BMI-matched controls [1]. Hyperadiponectinemia was 
found to be associated with chronic hyperglycemia in 
established T1DM and with catabolic state in other medical 
conditions, as anorexia nervosa [2].
It is unknown whether the association between hyper-
glycemia and high adiponectin level in T1DM may be 
attributed to the catabolic state present in decompensated 
diabetes.
Also, there is no available evidence on the factors asso-
ciated with serum adiponectin at diagnosis of the disease, 
when hypeglycaemia and catabolic state often coexist. 
Therefore, we evaluated the determinants of serum adi-
ponectin concentration in patients with newly diagnosed 
T1DM.
Patients and methods
We included 120 consecutive patients (40 women and 
80 men, aged 18–35 years, mean age 25 ± 5 years) 
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vs. 5.41 ± 3.17 µg/ml, p < 0.001) and in patients diag-
nosed with DKA than in other patients (8.75 ± 4.29 vs. 
5.77 ± 3.45 µg/ml, p < 0.001). Serum adiponectin con-
centration was also higher in patients positive for IA2-Ab 
than in IA2-Ab-negative subjects [6.32 (IQR: 4.15–8.69) 
vs. 4.31 (IQR: 2.89–7.38) µg/ml, p = 0.034] and in sub-
jects positive for three autoantibodies than in those posi-
tive only for one or two antibody specificities [6.87 (IQR: 
4.37–8.65) vs. 4.28 (IQR: 2.94–7.49) µg/ml, p = 0.018]. 
Adiponectin level correlated positively with HbA1c 
(r = 0.39, p < 0.001) and with relative weight loss before 
diagnosis (r = 0.20, p = 0.03), and negatively with BMI 
(r = −0.36, p < 0.001), systolic (r = −0.25, p = 0.005) 
and diastolic (r = −0.28, p = 0.002) blood pressure. 
Adiponectin concentration was negatively associated 
with baseline serum C-peptide concentration in men, but 
not in women (Spearman’s R: −0,35, p = 0.002). Adi-
ponectin level was not associated with plasma glucose, 
serum cholesterol (C), LDL-C, HDL-C and triglyceride 
concentration. In multivariate linear regression model, 
the association between adiponectin level and HbA1c 
remained significant after adjustment for age, sex, BMI, 
presence of DKA, and relative weight loss before diagno-
sis of diabetes [R2: 0.35, beta: 0.44 (95 % CI: 0.22–0.66), 
p < 0.001].
Discussion
In our study, we recruited the representative group of 
patients with newly diagnosed autoimmune T1DM. In our 
catchment area, these patients are routinely hospitalized in 
a single center irrespective of the severity of their clinical 
presentation, therefore the fact of hospitalization is unlikely 
to introduce significant selection bias. In our study, we 
found significant association between serum adiponec-
tin and HbA1c level, but not with glycaemia measured at 
diagnosis of diabetes. This finding may be explained by the 
greater stability of HbA1c level, which is also independent 
from transient confounders, as postprandial state, which 
significantly affect random glucose level. Similar associa-
tion between elevated serum adiponectin concentration and 
HbA1c or hyperglycemia has been reported in other studies 
[1], although not equivocally [3]. Higher serum adiponec-
tin concentration in patients with diabetic ketoacidosis at 
onset of T1DM may be attributed to the rise of adiponec-
tin in conditions associated with increased catabolism and 
cachexia. However, association between DKA and serum 
adiponectin concentration was insignificant after adjust-
ment for HbA1c. We also found a negative association 
between adiponectin and BMI at diagnosis and reported 
BMI before onset of symptoms of hyperglycaemia. The 
negative association between adiponectin and measures of 
insulin resistance was previously reported in patients with 
T1DM as in nondiabetic population [4]. Moreover, we 
noted the positive association between the degree of weight 
loss before T1DM diagnosis and adiponectin level which 
was not reported before. This may be explained either by 
greater relative weight loss occurring in overweight indi-
viduals or by the fact, that greater weight loss was associ-
ated with more severe presentation, significant catabolism 
and high prevalence of DKA. Higher adiponectin level in 
subjects positive for multiple islet autoantibodies may be 
also explained by more severe metabolic decompensation 
that was observed in these patients. Furthermore, we found 
negative association between serum C-peptide and adi-
ponectin in men. Absence of similar association in women 
may be explained by the relatively small group of female 
participants in our study. This finding is similar to a study 
performed in adults with T1DM history of over 5 years [5]. 
Given the cross-sectional design of the study, we were una-
ble to assess how body weight restoration and normaliza-
tion of hyperglycemia on insulin treatment affect adiponec-
tin value.
In our study, the association between HbA1c and adi-
ponectin level remained significant after adjustment for the 
variables that reflect the severity of presentation at onset, 
namely presence of DKA and magnitude of weight loss 
before diagnosis. This suggests that chronic hyperglycemia 
Table 1  Characteristics of 120 adults at diagnosis of type 1 diabetes
hsCRP serum C-reactive protein concentration measured with highly 
sensitive method; Means ± SD, Median (IQR) or n (%)
Parameter Value
Sex, n (M/F) 80/40
Age (years) 25 ± 5
Body mass index (kg/m2) 22.1 ± 3.2
Systolic blood pressure (mmHg) 117 ± 9
Diastolic blood pressure (mmHg) 76 ± 7
Glycaemia (mmol/l) 23.8 ± 8.8
C-peptide (μg/l) 0.82 (0.55–1.17)
HbA1c (%) 10.8 ± 2.3
Total cholesterol (mmol/l) 4.45 ± 1.33
LDL-cholesterol (mmol/l) 2.92 ± 1.05
HDL-cholesterol (mmol/l) 1.17 ± 0.29
Triglycerides (mmol/l) 1.15 (0.89–1.57)
hsCRP (mg/l) 0.77 (0.4–2.20)
Adiponectin (µg/ml) 5.10 (3.44–7.82)
Diabetic ketoacidosis, n (%) 23 (19 %)
Duration of symptoms before diagnosis (days) 28 (14–45)
Weight loss before diagnosis (kg) 6 (3–9)
Relative weight loss before diagnosis (% initial 
weight)
8.5 (3.8–13.2)
Current cigarette smokers, n (%) 50 (42 %)
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is the major determinant of increased adiponectin concen-
tration in patients with T1DM from the onset of the disease 
independently of the degree of metabolic decompensation 
and clinical indices of catabolism.
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